[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.   doi: 10.3322/caac.21442
[2]

Abdallah N, Rajkumar SV, Greipp P, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response[J/OL]. Blood Cancer J, 2020, 10(8): 82[2021-02-24]. https://www.nature.com/articles/s41408-020-00348-5. DOI: 10.1038/s41408-020-00348-5.
[3] Hillengass J, Usmani S, Rajkumar SV, et al.  International Myeloma Working Group consensus recommendations on maging in monoclonal plasma cell disorders[J]. Lancet Oncol, 2019, 20(6): e302-e312.   doi: 10.1016/S1470-2045(19)30309-2
[4] Palumbo A, Avet-Loiseau H, Oliva S, et al.  Revised international staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015, 33(26): 2863-2869.   doi: 10.1200/JCO.2015.61.2267
[5] Rajkumar SV.  Multiple myeloma: 2020 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(5): 548-567.   doi: 10.1002/ajh.25791
[6] Bartel TB, Haessler J, Brown TLY, et al.  18F-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma[J]. Blood, 2009, 114(10): 2068-2076.   doi: 10.1182/blood-2009-03-213280
[7] Zamagni E, Patriarca F, Nanni C, et al.  Prognostic relevance of 18F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation[J]. Blood, 2011, 118(23): 5989-5995.   doi: 10.1182/blood-2011-06-361386
[8] Patriarca F, Carobolante F, Zamagni E, et al.  The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1068-1073.   doi: 10.1016/j.bbmt.2015.03.001
[9] Russell SJ, Rajkumar SV.  Multiple myeloma and the road to personalised medicine[J]. Lancet Oncol, 2011, 12(7): 617-619.   doi: 10.1016/S1470-2045(11)70143-7
[10] 林志畑, 林晓平, 黄朝华.  18F-FDG PET/CT在初诊多发性骨髓瘤患者分期的临床应用[J]. 中山大学学报: 医学科学版, 2016, 37(6): 919-924.   doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2016.0127
Lin ZT, Lin XP, Huang CH.  Role of 18F-FDG PET/CT in newly diagnosed multiple myeloma[J]. J Sun Yat-sen Univ (Med Sci), 2016, 37(6): 919-924.   doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2016.0127
[11] 邸丽娟, 张建华, 王荣福, 等.  18F-FDG PET/CT可用于多发性骨髓瘤临床分期及病灶代谢活性评价[J]. 中华核医学与分子影像杂志, 2017, 37(1): 35-38.   doi: 10.3760/cma.j.issn.2095-2848.2017.01.009
Di LJ, Zhang JH, Wang RF, et al.  18F-FDG PET/CT in staging and metabolic activity assessment of multiple myeloma[J]. Chin J Nucl Med Mol Imaging, 2017, 37(1): 35-38.   doi: 10.3760/cma.j.issn.2095-2848.2017.01.009
[12] Park S, Lee SJ, Chang WJ, et al.  Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients[J]. Acta Haematol, 2014, 131(4): 193-199.   doi: 10.1159/000354839
[13] Abe Y, Narita K, Kobayashi H, et al.  Medullary abnormalities in appendicular skeletons detected with 18F-FDG PET/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with high-risk factors[J]. Am J Roentgenol, 2019, 213(4): 918-924.   doi: 10.2214/AJR.19.21283
[14] Moon SH, Choi WH, Yoo IR, et al.  Prognostic value of baseline 18F-fluorodeoxyglucose PET/CT in patients with multiple myeloma: a multicenter cohort study[J]. Korean J Radiol, 2018, 19(3): 481-488.   doi: 10.3348/kjr.2018.19.3.481
[15]

Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice[J/OL]. Blood Cancer J, 2015, 5(10): e365[2021-02-24]. https://www.nature.com/articles/bcj201592. DOI: 10.1038/bcj.2015.92.
[16] Moreau P, Attal M, Caillot D, et al.  Prospective evaluation of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study[J]. J Clin Oncol, 2017, 35(25): 2911-2918.   doi: 10.1200/JCO.2017.72.2975
[17] Tu HL, He Y, Huang TH, et al.  Predictive value of 18F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma[J]. Eur J Haematol, 2018, 100(2): 189-197.   doi: 10.1111/ejh.13006